Precision Health Research Singapore

What Precision Health Research Singapore does

Precision Health Research Singapore (PRECISE) is the central coordinating entity for Singapore's National Precision Medicine (NPM) Programme, operating as a business unit under the Consortium for Clinical Research and Innovation Singapore (CRIS), a subsidiary of Ministry of Health Holdings. Established in April 2021 to drive Phase II of the national precision medicine strategy (launched in 2017 under RIE 2020), PRECISE coordinates population-scale research across three sequential phases: SG10K_Health (Phase I, ~10,000 genomes completed October 2019), PRECISE-SG100K (Phase II, ~100,000 participants recruited and whole genome sequenced at 30X coverage by mid-2025), and SG INSIGHT (Phase III, targeting 400,000–450,000 participants from healthcare settings by 2031 to cover ~10% of Singapore's resident population).

PRECISE's core technological platform integrates whole genome sequencing, proteomics, metabolomics, and linked Electronic Health Records across Singapore's multi-ethnic Asian population (71% Chinese, 14% Malay, 15% Indian, capturing an estimated 80% of Asia's genetic diversity). Supporting infrastructure includes the SG10K_Health Portal (CHORUS Variant Browser, CHORUS Beacon, SNPdrug3D, Polygenic Risk Score tools), the TRUST platform (national data governance framework for secure data access), the GLOW multi-omics platform (gut microbiome and mental health), and Clinical Implementation Pilots embedding genetic testing into hospital pathways. Technology partnerships span Illumina, Oxford Nanopore, PacBio, Thermo Fisher Scientific, and Seer for sequencing and proteomics.

The business model is government-funded rather than commercial. PRECISE receives funding from Singapore's National Research Foundation and the Ministry of Health's National Medical Research Council under the RIE2025 strategy. There is no commercial pricing; data access is provided to qualified Singapore public academic and clinical researchers through Calls for Proposals (CFP) without direct revenue capture from researchers, while the Pharma Collaboration Committee (PCC) model — now with five pharma partners including GSK and Boehringer Ingelheim — represents an industry engagement channel. PRECISE serves Singapore residents (as participants), public academic and clinical researchers (as data users), three public healthcare clusters (NHG Health, NUHS, SingHealth) as Phase III implementation partners, and pharmaceutical companies as PCC collaborators.

Name

Precision Health Research Singapore

Legal name

Precision Health Research, Singapore (PRECISE)

Website

https://npm.sg

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Precision Health Research Singapore (PRECISE) is a government research entity coordinating Singapore's National Precision Medicine Programme, building population-scale whole genome, proteomic, and clinical datasets across a multi-ethnic Asian population to serve public researchers, healthcare clusters, and pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Precision Medicine Research

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Population Genomics & Preventive Precision Health Programs (HLAAANAL)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM), National Public Health Reference Laboratories (HLAJAIAA)

Keywords

• Population genomics research
• Precision medicine program
• Whole genome sequencing
• Clinical data governance
• Multi-omics research

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Research Programme Funding: PRECISE is a government-funded national research programme supported by the National Research Foundation Singapore (NRF) and Singapore Ministry of Health's National Medical Research Council. It operates as a business unit under the Consortium for Clinical Research and Innovation Singapore (CRIS), a subsidiary of Ministry of Health Holdings.
2. Data Access Services: Provides controlled data access to qualified institutional researchers through the TRUST platform. Data access is governed by Data Access Committees with associated platform costs. No direct revenue from researchers as CFP does not provide funding.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

PRECISE coordinates Singapore's National Precision Medicine (NPM) Programme across multiple phases, building and curating population-scale genomic, proteomic, and clinical datasets (SG10K_Health, PRECISE-SG100K, SG INSIGHT). It provides qualified researchers with controlled data access via the TRUST platform, supports Clinical Implementation Pilots that embed genetic testing into hospital pathways, and runs translational research programmes such as GLOW for gut-brain-mental health. Its outputs are population genomic resources, research coordination, and clinical implementation support rather than commercial products.

Product overview

Precision Health Research Singapore (PRECISE) coordinates Singapore's multi-phase National Precision Medicine (NPM) Programme as a research coordinating entity rather than a commercial product company. The core offerings include the SG10K_Health Portal with variant analysis tools, the PRECISE-SG100K Resource (a population-scale genomic and clinical dataset of ~100,000 Singaporeans), and the Phase III SG INSIGHT initiative targeting 10% of Singapore's population. Supporting services include data access through the TRUST platform, Clinical Implementation Pilots for embedding genomic testing in healthcare, and the GLOW Programme for microbiome-mental health research. These programs collectively build infrastructure for translating large-scale biological data into precision medicine applications.

Differentiator

Problem solved

Functional benefit

Brands

• PRECISE-SG100K: Population-scale biobank study with ~100,000 Singaporean participants generating whole genome sequencing data
• SG10K_Health
• GLOW
• CIP
• SG INSIGHT
• TRUST Platform

Products and services

• SG10K_Health Portal Web services platform providing qualified researchers access to genetic datasets from Singapore's first precision medicine phase, including variant browsers, polygenic risk scores, and protein-drug interaction queries for ~10,000 Singaporeans.
• PRECISE-SG100K Resource Multi-ancestry Asian population cohort dataset comprising ~100,000 Singaporean participants with integrated whole genome sequencing (30X), research phenotype data and linked Electronic Health Records, made available to approved researchers via the TRUST platform.
• SG INSIGHT (Phase III) Population-scale implementation phase sequencing whole genomes of about 10% of Singapore's resident population and establishing Genomic Innovation Hubs across NHG Health, NUHS and SingHealth to drive clinical integration of precision medicine.
• TRUST Platform Access National data governance and analytics platform enabling secure, pseudonymised access to linked genomic, clinical and phenotypic data for approved research projects, with Data Access Committees and a compute Charging Framework.
• Data Access Services

Quantifiable outcome

• 98.3 million previously unreported genetic variants identified
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Twelve partnerships are on record, tiered strategic and core.

• GSKstrategicStrategic or Co-development Partner · 5 May 2026GSK joins PRECISE-SG100K Pharma Collaboration Committee (PCC) as 5th pharma partner, enabling industry collaboration in precision medicine research.
• HealthVeritystrategicTechnology or Integration · 15 April 2026Thermo Fisher partnership with HealthVerity giving PPD clinical research business access to over 270 million de-identified U.S. patient records for trial feasibility, recruitment, and real-world evidence. Part of broader precision health ecosystem.
• Thermo Fisher ScientificcoreTechnology or Integration · 9 April 2026Strategic collaboration to support PRECISE-SG100K study, one of Southeast Asia's most ambitious population-scale biobank initiatives. Thermo Fisher deploying Olink Proximity Extension Assay platforms and Orbitrap Astral mass spectrometry system for scalable, high-sensitivity proteomic data generation.
• Seer, Inc.coreTechnology or Integration · 9 April 2026Collaboration for proteomics analysis on 10,000 samples for landmark population-scale study. Seer's Proteograph Product Suite integrated with Thermo Fisher platforms for scalable protein measurement and biomarker discovery.
• IlluminacoreTechnology or Integration · 4 January 2026Partnership with genomics companies including Illumina, Oxford Nanopore Technologies, and PacBio for Phase II of Singapore's National Precision Medicine programme advancing Asian genomic research.
• Oxford Nanopore TechnologiescoreTechnology or Integration · 4 January 2026Partnership with genomics companies for Phase II of National Precision Medicine programme, enabling long-read sequencing capabilities for population-scale genomic research.
• PacBiocoreTechnology or Integration · 4 January 2026Partnership with genomics companies for Phase II of National Precision Medicine programme. PacBio SMRT cells used in Long Read Sequencing Call for Sample Submission, with 4 projects selected in March 2024.
• University of Wisconsin-MadisoncoreStrategic or Co-development Partner · 20 December 2025International collaboration extending GLOW programme beyond Asia. Researchers at UW-Madison's Wisconsin Institute for Discovery and Centre for Healthy Minds recruiting 1,500 U.S. participants to complement Singapore cohort, enabling cross-population analysis of gut microbiome and mental health.
• IlluminacoreTechnology or Integration · 10 November 2025Illumina's Protein Prep solution deployed in Asia Pacific region including collaborations with PRECISE-SG100K for proteomics research capabilities.
• Boehringer IngelheimstrategicStrategic or Co-development Partner · 2 October 2023Partnership with Boehringer Ingelheim to advance precision medicine research and clinical innovation in Singapore.
• Genome Institute of Singapore (GIS, A*STAR)coreStrategic or Co-development PartnerPartnership with GIS for whole genome sequencing under Phase II of National Precision Medicine Programme. GIS generates 30X coverage WGS data for 100K participants.
• SG100K Institutions (HELIOS-NTU, SPHS-NUS, SEED-SERI, SingHeart-NHCS)coreStrategic or Co-development PartnerFour longitudinal population health cohorts providing research phenotype data and participants for PRECISE-SG100K resource: Health for Life in Singapore (HELIOS), Singapore Population Health Studies (SPHS), Singapore Epidemiology of Eye Diseases (SEED), and SingHeart.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• UK Biobank: Large-scale biomedical database with 500,000+ participants and extensive genomic, lifestyle, and health outcome data — sets the global benchmark for population-scale research resources against which PRECISE's Asian dataset is differentiated.
• Illumina: Dominant genomic sequencing technology provider and PRECISE's core sequencing partner — relevant as an ecosystem incumbent whose platform decisions directly shape PRECISE's technical roadmap and downstream pharma research workflows.

Direct peers

• Genomics England: UK government-backed programme sequencing 100,000+ participants and operating as a national genomic medicine platform with healthcare system integration — closely mirrors PRECISE's coordinating role, data governance model, and clinical translation focus, but in a European population context.
• deCODE genetics (Amgen): Population genomics company built on Iceland's national health records and genealogy — directly comparable as a population-scale WGS programme leveraging a small, genetically homogeneous population, although now commercialised under Amgen.
• NIH All of Us Research Program: US national population genomics programme targeting 1 million+ participants with linked EHRs and a researcher data access platform — directly comparable to PRECISE-SG100K in cohort design, data scope, and federal funding model.
• FinnGen: Public-private Finnish genomics programme combining genomic data with national health registries for biobank-scale drug discovery — analogous in combining national funding, pharma partnerships, and registry-linked genomic data.
• Estonian Biobank (University of Tartu): National population biobank with linked health records covering ~20% of Estonia's adult population — comparable in scale ambition, government backing, and integration of genomic + clinical data for translational research.

Emerging players

• Human Cell Atlas: International consortium building comprehensive single-cell reference maps of human biology — comparable in scale, international collaboration model, and data governance ambitions, although focused on cellular rather than genomic diversity.

Regional players

• Australian Genomics: Australian national genomics collaboration supporting clinical genomics implementation across research and healthcare — comparable as an Asia-Pacific national programme but focused on rare disease flagship cohorts rather than population-scale WGS.
• Genome Institute of Singapore (A*STAR GIS): Singapore's national genomics research institute under A*STAR — closely linked to PRECISE as both partner (WGS production) and talent source (shared Executive Director), operating as a more discovery-oriented counterpart to PRECISE's programme-coordinating role.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/crissg
• YouTubeyoutube.com/channel/UCj5L2X6lc1bU2SFK5VOGh5g

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precision Health Research Singapore